122
Participants
Start Date
February 28, 2013
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
RO5503781 MBP
Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
RO5503781 SDP
Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
Idarubicin
Idarubicin will be administered as per standard clinical practice.
Daunorubicin
Daunorubicin will be administered as per standard clinical practice.
Cytarabine
Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.
Peter Maccallum Cancer Centre, Melbourne
New York Medical College, Valhalla
Institut J Paoli I Calmettes; Onco Hematologie 2, Marseille
Thomas Jefferson University, Philadelphia
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpigh, Bologna
Cancer Therapy & Research Ctr; Dept Institute for Drug Development, San Antonio
USC Norris Cancer Center, Los Angeles
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal
Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul
Asan Medical Center, Seoul
The Beatson West of Scotland Cancer Centre; Cancer Clinical Trials Unit, Glasgow
Hoffmann-La Roche
INDUSTRY